Efficacy and Safety of World Health Organization Group 5 Drugs for Multidrug-Resistant Tuberculosis Treatment

European Respiratory Journal - United Kingdom
doi 10.1183/13993003.00649-2015
Full Text
Abstract

Available in full text

Date
Authors
Publisher

European Respiratory Society (ERS)

Related search

Drug-Resistant Tuberculosis and Group 5 Anti-Tuberculosis Drugs

Archives of Pediatric Infectious Diseases
Child HealthInfectious DiseasesPediatricsPerinatology
2015English

Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2013English

Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2016English

Linezolid Safety, Tolerability and Efficacy to Treat Multidrug- And Extensively Drug-Resistant Tuberculosis

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2011English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases
Infectious Diseases
2019English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Health System Delay in Treatment of Multidrug Resistant Tuberculosis Patients in Bangladesh

BMC Infectious Diseases
Infectious Diseases
2015English

New Drugs to Treat Multidrug-Resistant Tuberculosis: The Case for Bedaquiline

Therapeutics and Clinical Risk Management
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy